Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pembrolizumab with chemoradiotherapy, with or without olaparib, in newly diagnosed limited-stage small cell lung cancer
MOH_2021-10-13_010320Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in small cell lung cancer (SCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2021; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2021-10-13_010320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-13_010320.